Galen Growth | Decision-Grade Digital Health Intelligence published an op-ed testing the thesis that more than 90% of drugs failing clinical trials are engineered just fine and the biological mechanism is wrong against HealthTech Alpha data.

Galen Growth helps healthcare organisations make more informed decisions about Digital Health innovation. We support corporate innovation, strategy, partnership and investment teams answering critical questions: Where is the market moving? Which companies and technologies matter? Which partners are ready to scale? Where are competitors placing their bets? What should we build, buy, partner with or invest in? Our work is powered by HealthTech Alpha, Galen Growth’s proprietary Digital Health intelligence platform. It combines globally structured company, product, funding, partnership, clinical, regulatory and market data with a specialist taxonomy and more than a decade of Digital Health expertise. Organisations use Galen Growth for market mapping, innovation scouting, partner identification, competitive intelligence, corporate venture strategy, M&A screening, commercial due diligence and portfolio assessment. We work with healthcare companies, investors, health systems and professional-services firms that need evidence they can defend—not simply more information. Contact Galen Growth to discuss your strategic question, request a HealthTech Alpha demonstration or commission a decision-grade market analysis.

Founded 2016